Selling, General, and Administrative Costs: Bio-Techne Corporation vs Evotec SE

A Tale of Two Biotech Giants: Bio-Techne Corporation vs. Evotec SE

In the dynamic world of biotechnology, understanding financial health is crucial. Over the past decade, Bio-Techne Corporation and Evotec SE have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Bio-Techne's SG&A expenses surged by over 550%, reflecting its aggressive expansion and investment in innovation. In contrast, Evotec SE's expenses grew by approximately 840%, indicating its strategic scaling efforts.

Bio-Techne's expenses peaked in 2024, while Evotec's data for the same year remains elusive, hinting at potential strategic shifts. The year 2021 marked a significant leap for both, with Bio-Techne's expenses rising by 25% and Evotec's by 37% from the previous year. These figures underscore the companies' commitment to growth and adaptation in a competitive market. As the biotech landscape evolves, these financial insights offer a glimpse into the strategic priorities of these industry leaders.